Janssen pulls plug on Alzheimer’s candidate
Safety concerns have prompted Janssen to pull the plug on a development programme testing the BACE inhibitor atabecestat for Alzheimer’s disease.
Read More
Tag: verubecestat
MSD’s verubecestat fails again in Alzheimer’s trial
The Alzheimer’s disease research field has taken yet another hit with the failure of MSD’s verubecestat in a late-stage trial.
Read More
Merck pulls plug on late-stage Alzheimer’s trial
Merck & Co has terminated a Phase II/III trial testing its investigational medicine verubecestat in patients with mild to moderate Alzheimer’s disease.
Read More
Merck drug shows promise in Alzheimer’s disease
Merck & Co’s BACE1 inhibitor verubecestat has shown promise in a Phase I trial assessing its potential in Alzheimer’s disease.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
